home / stock / meip / meip short
Short Information | MEI Pharma Inc. (NASDAQ:MEIP)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 61,581 |
Total Actual Volume | 363,819 |
Short Trends | |
---|---|
Cover Days | 19 |
Short Days | 1 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 3,079 |
Average Short Percentage | 19.33% |
Is there a MEIP Short Squeeze or Breakout about to happen?
See the MEIP Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
04-25-2024 | $3.26 | $3.1 | $3.26 | $3.1 | 16,736 | 3,608 | 21.56% |
04-24-2024 | $3.38 | $3.26 | $3.45 | $3.22 | 7,394 | 1,816 | 24.56% |
04-23-2024 | $3.33 | $3.3323 | $3.3323 | $3.2401 | 5,008 | 662 | 13.22% |
04-22-2024 | $3.22 | $3.37 | $3.37 | $3.22 | 6,549 | 1,391 | 21.24% |
04-19-2024 | $3.275 | $3.25 | $3.3 | $3.22 | 26,402 | 1,052 | 3.98% |
04-18-2024 | $3.31 | $3.25 | $3.38 | $3.25 | 12,047 | 7,134 | 59.22% |
04-17-2024 | $3.25 | $3.31 | $3.44 | $3.2 | 9,086 | 3,066 | 33.74% |
04-16-2024 | $3.27 | $3.2 | $3.4433 | $3.2 | 16,466 | 3,429 | 20.82% |
04-15-2024 | $3.34 | $3.25 | $3.36 | $3.23 | 13,289 | 1,258 | 9.47% |
04-12-2024 | $3.79 | $3.27 | $3.79 | $3.21 | 22,242 | 3,819 | 17.17% |
04-11-2024 | $3.77 | $3.63 | $3.8343 | $3.61 | 35,872 | 1,357 | 3.78% |
04-10-2024 | $3.82 | $3.76 | $3.84 | $3.7501 | 15,789 | 515 | 3.26% |
04-09-2024 | $3.795 | $3.82 | $3.88 | $3.795 | 10,894 | 2,752 | 25.26% |
04-08-2024 | $3.78 | $3.83 | $3.875 | $3.7124 | 16,398 | 5,702 | 34.77% |
04-05-2024 | $3.87 | $3.75 | $3.87 | $3.75 | 10,469 | 299 | 2.86% |
04-04-2024 | $4.01 | $3.95 | $4.06 | $3.8 | 15,662 | 1,727 | 11.03% |
04-03-2024 | $4.02 | $4.05 | $4.0651 | $3.85 | 25,338 | 8,112 | 32.02% |
04-02-2024 | $3.85 | $4 | $4.1099 | $3.839 | 31,958 | 6,927 | 21.68% |
04-01-2024 | $4 | $3.8841 | $4 | $3.85 | 52,886 | 4,507 | 8.52% |
03-28-2024 | $3.92 | $4 | $4.1473 | $3.8113 | 13,334 | 2,448 | 18.36% |
News, Short Squeeze, Breakout and More Instantly...
– MEI Pharma Board Unanimously Determines, Based on Clinical Data Results, Not to Proceed with Second Capital Return Under 2023 Anson and Cable Car Cooperation Agreement: Conserving Capital, Prioritizing Measured Investment, Extending Operational Runway – MEI Pharma, Inc. ...
– Cohort 1 Exceeds Predetermined Non-Progression Threshold in the Ongoing Phase 1b Study – – ME-344 in Combination with Bevacizumab was Generally Well-tolerated with no Evidence of Overlapping Toxicity – – MEI to Continue Advancing ME-344 via Dev...
MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today announced that David Urso, president and chief executive officer of MEI Pharma, will participate in a firesi...